

2023 KENTUCKY CANCER ACTION DAY



AGENDA



- 8:00 AM** Check-In, Breakfast, and Networking
- 8:20 AM** Welcome - Shannon Baker & Doug Hogan
- 8:30 AM** Senator Meredith Remarks
- 8:40 AM** Representative Moser Remarks
- 8:50 AM** 2023 Legislative Priorities - Doug Hogan and Shannon Baker
- 9:10 AM** Meeting with Legislators Briefings- Allison Adams & Katie Rose Garden
- 9:25 AM** Q&A's, Group photo, and Send off to Meetings
- 9:30-11:45 AM** Meetings - Legislative meetings/Offices
Report Back Forms - Online
- 12:00-1:00 PM** Optional-Room 149-Health Committee Hearing on Biomarker Bill H.B 180 and recognition in the committee.



#PRECISIONMATTERSKY
#KYCancerActionDay

2023 KENTUCKY CANCER ACTION DAY

Hook, Line, and Sinker

Hook

The meeting leader introduces the group (name + where you live)

• I am here as a volunteer for ACS CAN. We are meeting with legislators today to discuss our legislative priority issue, Biomarkers.

Line

Explain the need:

- (INSERT why this is needed/impact on state/why important for cancer etc.)
-
- Tell your personal story: Connect your personal story to the importance of the ask/issue

Sinker

Make the Ask again

Record the answer the lawmaker made to our ask.

**Don't forget the "thank you"!
The appreciation goes a long way**



#PRECISIONMATTERSKY
#KYCancerActionDay

2023 KENTUCKY CANCER ACTION DAY Lawmaker Mtg Info

Find who represents you! Scan here

House:

Senate:



Meeting Outline:

Hook: Leader makes introductions.

Line: Explain the need.

Sinker: Make the ask.



Reminders:

Be polite and professional to lawmakers and staff.

It is okay to look at your notes!

Your personal story matters more than anything else.

Your legislators work for you and your voice matters!



#PRECISIONMATTERSKY
#KYCancerActionDay

2023 KENTUCKY CANCER ACTION DAY

NEXT STEPS!

How was your meeting? Let us know by completing the Report Back Form Online or Offline. One form per lawmaker meeting.



Scan to complete the
Online Report Back Form

Sample Social Media Posts:

Thank you @LAWMAKERHANDLE, for meeting with @KYACSCAN volunteers and staff during #KYCancerActionDay!
#PRECISIONMATTERSKY

We are in Frankfort meeting with lawmakers to discuss issues affecting cancer patients #KYCancerActionDay
#PRECISIONMATTERSKY (attach photo)

Stay Involved:

Email Katie Rose Garden, Kentucky Grassroots Manager, to become more involved at katie.garden@cancer.org



#PRECISIONMATTERSKY
#KYCancerActionDay

Biomarker Testing



We ask you to support the passage of HB 180 to expand appropriate coverage of biomarker testing for state governed commercial insurance and Medicaid plans.

- Timely biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer.
- Biomarker testing is a key to unlocking precision or personalized medicine.
- Biomarker testing is a part of standard of care treatment for many cancer patients, but insurance coverage is failing to keep pace.
- Nearly 60% of all cancer drugs approved in the last 5 years require or recommend biomarker testing before use.
- The number & percentage of cancer clinical trials that involve biomarkers has grown significantly, from 15% in 2000 to 55% in 2018.
- In a 2021 survey, 66% of oncology providers reported that insurance coverage for biomarker testing is a significant or moderate barrier for their patients to access biomarker testing.

Biomarker Testing



We ask you to support the passage of HB 180 to expand appropriate coverage of biomarker testing for state governed commercial insurance and Medicaid plans.

- Timely biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer.
- Biomarker testing is a key to unlocking precision or personalized medicine.
- Biomarker testing is a part of standard of care treatment for many cancer patients, but insurance coverage is failing to keep pace.
- Nearly 60% of all cancer drugs approved in the last 5 years require or recommend biomarker testing before use.
- The number & percentage of cancer clinical trials that involve biomarkers has grown significantly, from 15% in 2000 to 55% in 2018.
- In a 2021 survey, 66% of oncology providers reported that insurance coverage for biomarker testing is a significant or moderate barrier for their patients to access biomarker testing.

Biomarker Testing



We ask you to support the passage of HB 180 to expand appropriate coverage of biomarker testing for state governed commercial insurance and Medicaid plans.

- Timely biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer.
- Biomarker testing is a key to unlocking precision or personalized medicine.
- Biomarker testing is a part of standard of care treatment for many cancer patients, but insurance coverage is failing to keep pace.
- Nearly 60% of all cancer drugs approved in the last 5 years require or recommend biomarker testing before use.
- The number & percentage of cancer clinical trials that involve biomarkers has grown significantly, from 15% in 2000 to 55% in 2018.
- In a 2021 survey, 66% of oncology providers reported that insurance coverage for biomarker testing is a significant or moderate barrier for their patients to access biomarker testing.

Biomarker Testing



We ask you to support the passage of HB 180 to expand appropriate coverage of biomarker testing for state governed commercial insurance and Medicaid plans.

- Timely biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer.
- Biomarker testing is a key to unlocking precision or personalized medicine.
- Biomarker testing is a part of standard of care treatment for many cancer patients, but insurance coverage is failing to keep pace.
- Nearly 60% of all cancer drugs approved in the last 5 years require or recommend biomarker testing before use.
- The number & percentage of cancer clinical trials that involve biomarkers has grown significantly, from 15% in 2000 to 55% in 2018.
- In a 2021 survey, 66% of oncology providers reported that insurance coverage for biomarker testing is a significant or moderate barrier for their patients to access biomarker testing.

--	--

KENTUCKY 2023 LEGISLATIVE ASKS



1 Kentucky Biomarker Insurance Coverage

Access to appropriate biomarker testing can help to achieve: better health outcomes, improved quality of life, reduced costs.

Without action, this could increase existing disparities in health outcomes by race, ethnicity, income and geography.

Insurance coverage for biomarker testing is failing to keep pace with innovation and advancement in treatment:

66% of oncology providers reported that insurance coverage is a significant or moderate barrier to appropriate biomarker testing for their patients.

Arizona, Illinois, Louisiana and Rhode Island have recently passed legislation to expand coverage of comprehensive biomarker testing.

In Pennsylvania: 32% of commercial insurance plans provide coverage that is more restrictive than National Comprehensive Cancer Network guidelines.

The ASK: Will you support the passage of HB 180 to expand appropriate coverage of biomarker testing for public and private insurance plans?

- Timely biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer.
 - Biomarker testing is a key to unlocking precision or personalized medicine.
 - Biomarker testing is a part of the standard of care treatment for many cancer patients, but insurance coverage is failing to keep pace.
 - Nearly 60% of all cancer drugs approved in the last 5 years require or recommend biomarker testing before use.
 - The number & percentage of cancer clinical trials that involve biomarkers have grown significantly, from 15% in 2000 to 55% in 2018.
 - In a 2021 survey, 66% of oncology providers reported that insurance coverage for biomarker testing is a significant or moderate barrier for their patients to access biomarker testing.
-